- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Nasdaq
Wall Street JournalEN
C
CNTX
Context Therapeutics Inc
2.24
-0.08-3.45%After Hours: 2.230 -0.01 -0.45%19:46 02/20 EST
OPEN/PREV CLOSE2.320/2.320
TODAY RANGE2.240-2.360
VOL539.95K
MARKET CAP205.81M
52 WEEK RANGE0.4900-2.850
AVG VOL (3M)1.51M
% TURNOVER0.59%
TURNOVER--
P/E (TTM)-7.9040
% RANGE5.17%
EPS(TTM)-0.2834
P/E(FORWARD)-6.4000
P/B2.813
BVPS0.7964
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP203.24M
SHARES OUTSTANDING91.88M
NEXT EARNINGS03/12-03/20
FREE FLOAT90.73M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Reuters·02/09 12:30
Context Therapeutics nimmt an mehreren Investorenkonferenzen teil
Reuters·02/09 12:30
Context Therapeutics Inc. to Present at Key Investor Conferences
TipRanks·01/23 12:48
JonesTrading Sticks to Its Buy Rating for Context Therapeutics (CNTX)
TipRanks·01/08 12:57
Context Therapeutics Highlights T Cell Engager Pipeline Strategy
TipRanks·12/22/2025 12:16
Context Therapeutics initiated with a Buy at JonesResearch
Reuters·12/22/2025 12:07
CONTEXT THERAPEUTICS <CNTX.O>: JONESTRADING INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $7
Reuters·12/22/2025 07:49
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Reuters·12/16/2025 17:18
CANCER DRUG DEVELOPERS SECURE REGULATORY CLARITY AS FDA RESHAPES APPROVAL STANDARDS
Reuters·11/13/2025 21:08
BioAtla Reports Lower Q3 R&D Expenses and Confirms Partnership Plans by Year End
TipRanks·11/07/2025 17:56
Buy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments
Reuters·11/07/2025 12:30
Context Therapeutics Advances CT-95 and CT-202 Programs Toward Clinical Trials
Same Industry
Name/Symbol
Change%
Price